[go: up one dir, main page]

MA41139A - Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 - Google Patents

Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1

Info

Publication number
MA41139A
MA41139A MA041139A MA41139A MA41139A MA 41139 A MA41139 A MA 41139A MA 041139 A MA041139 A MA 041139A MA 41139 A MA41139 A MA 41139A MA 41139 A MA41139 A MA 41139A
Authority
MA
Morocco
Prior art keywords
pharmaceutical combination
combination including
selective agonist
receptor selective
sip1 receptor
Prior art date
Application number
MA041139A
Other languages
English (en)
Inventor
Martine Clozel
Luca Piali
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA41139A publication Critical patent/MA41139A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
MA041139A 2014-12-11 2015-12-09 Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 MA41139A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2014077469 2014-12-11

Publications (1)

Publication Number Publication Date
MA41139A true MA41139A (fr) 2017-10-17

Family

ID=54848562

Family Applications (2)

Application Number Title Priority Date Filing Date
MA041139A MA41139A (fr) 2014-12-11 2015-12-09 Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
MA41481A MA41481B1 (fr) 2014-12-11 2015-12-10 Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA41481A MA41481B1 (fr) 2014-12-11 2015-12-10 Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Country Status (23)

Country Link
US (6) US10245253B2 (fr)
EP (2) EP4620526A3 (fr)
JP (3) JP6437119B2 (fr)
KR (3) KR101996245B1 (fr)
CN (1) CN106999462B (fr)
AU (1) AU2015359306B2 (fr)
BR (1) BR112017012396B1 (fr)
CA (1) CA2964616C (fr)
CL (1) CL2017001479A1 (fr)
CY (1) CY2022011I2 (fr)
EA (2) EA039629B1 (fr)
ES (1) ES3053660T3 (fr)
HK (1) HK1245106A1 (fr)
HR (1) HRP20251463T1 (fr)
IL (2) IL252701B (fr)
MA (2) MA41139A (fr)
MX (2) MX382489B (fr)
PH (1) PH12017501060B1 (fr)
SA (1) SA517381489B1 (fr)
SG (1) SG11201704569SA (fr)
SM (1) SMT202500469T1 (fr)
UA (1) UA122063C2 (fr)
WO (1) WO2016092042A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
PL3256125T3 (pl) 2014-12-11 2022-05-09 Actelion Pharmaceuticals Ltd Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
EP4146190A2 (fr) * 2020-05-06 2023-03-15 Imcyse SA Polythérapie pour le traitement de maladies associées au fumarate
US20240368065A1 (en) * 2021-04-23 2024-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Citraconic acid and derivatives thereof for use as a medicament
KR20230120768A (ko) 2022-02-10 2023-08-17 하나 영농조합법인 양념 핫소스와 그 제조방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
BRPI0412380A (pt) 2003-07-08 2006-09-19 Novartis Ag compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
CN100567275C (zh) 2003-11-21 2009-12-09 埃科特莱茵药品有限公司 作为免疫抑制剂的5-(苯基-(z)-亚基)-噻唑烷-4-酮衍生物
CN1922135B (zh) 2004-02-24 2011-07-06 Irm责任有限公司 免疫抑制剂化合物和组合物
ES2582942T3 (es) * 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
EP2384749A1 (fr) 2004-11-29 2011-11-09 Novartis AG Posologie d'un agoniste du récepteur S1P
US7879821B2 (en) 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
CN103087004A (zh) 2006-11-23 2013-05-08 埃科特莱茵药品有限公司 一种制备2-亚氨基-四氢噻唑-4-酮衍生物的新方法
PL2137537T3 (pl) 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
EP2177521A1 (fr) 2008-10-14 2010-04-21 Almirall, S.A. Nouveaux dérivés de 2-amidothiadiazole
GB0819182D0 (en) * 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
EP2370438A1 (fr) 2008-12-04 2011-10-05 Exelixis, Inc. Dérivés d`imidazo[1,2a]pyridine, leur emploi en tant qu'agonistes de s1p1 et leurs méthodes de production
RS59857B1 (sr) 2008-12-22 2020-02-28 Novartis Ag Režim doziranja agonista s1p receptora
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
ES2411972T5 (es) 2009-01-09 2021-10-27 Fwp Ip Aps Formulación farmacéutica que comprende uno o más ésteres de ácido fumárico en una matriz de erosión
EP2210890A1 (fr) 2009-01-19 2010-07-28 Almirall, S.A. Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
US20100260755A1 (en) 2009-04-09 2010-10-14 Medicinova, Inc. Ibudilast and immunomodulators combination
EP2305660A1 (fr) 2009-09-25 2011-04-06 Almirall, S.A. Nouveaux dérivés de thiadiazole
CA2782415A1 (fr) 2009-12-01 2011-06-09 Metanomics Health Gmbh Moyens et methodes permettant de diagnostiquer la sclerose en plaques
EP2343287A1 (fr) 2009-12-10 2011-07-13 Almirall, S.A. Nouveaux dérivés de 2-aminothiadiazole
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
EP2366702A1 (fr) 2010-03-18 2011-09-21 Almirall, S.A. Nouveaux dérivés d'oxadiazole
EP2390252A1 (fr) 2010-05-19 2011-11-30 Almirall, S.A. Nouveaux dérivés de pyrazole
EP2455080A1 (fr) 2010-11-23 2012-05-23 Almirall, S.A. Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques
US20140163100A1 (en) 2011-05-26 2014-06-12 Biogen Idec Ma Inc. Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
JP2014517300A (ja) 2011-05-31 2014-07-17 メタノミクス ヘルス ゲーエムベーハー 多発性硬化症を診断する方法
AU2013203445C1 (en) 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US20130314669A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Method and system for assessing visual disorder
ES2671194T3 (es) 2012-07-27 2018-06-05 Biogen Ma Inc. Compuestos que son agentes moduladores de S1P y/o agentes moduladores de ATX
EP2692343A1 (fr) * 2012-08-03 2014-02-05 Forward Pharma A/S Polythérapie pour le traitement de la sclérose en plaques
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
ES2691793T3 (es) 2012-08-06 2018-11-28 Biogen Ma Inc. Derivados de naftaleno 1,5,6-sustituidos como moduladores de receptor de 1-fosfato de esfingosina (S1P) y/o autotaxina (ATX) para tratar trastornos inflamatorios y autoinmunitarios
HK1211361A1 (en) 2012-08-13 2016-05-20 Biogen Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
US9340518B2 (en) 2012-08-17 2016-05-17 Actelion Pharmaceuticals Ltd. Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US20150238602A1 (en) 2012-10-09 2015-08-27 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
US20150157590A9 (en) 2012-11-05 2015-06-11 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
US8669281B1 (en) * 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
EP3062792A1 (fr) 2013-11-01 2016-09-07 Celgene International II Sarl Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant
PL3256125T3 (pl) 2014-12-11 2022-05-09 Actelion Pharmaceuticals Ltd Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1

Also Published As

Publication number Publication date
HK1245106A1 (zh) 2018-08-24
US20170348287A1 (en) 2017-12-07
US10245253B2 (en) 2019-04-02
MA41481A (fr) 2017-12-19
IL252701B (en) 2022-01-01
MX382489B (es) 2025-03-13
KR20190077131A (ko) 2019-07-02
ES3053660T3 (en) 2026-01-23
US11026927B2 (en) 2021-06-08
IL252701A0 (en) 2017-08-31
SMT202500469T1 (it) 2026-01-12
SA517381489B1 (ar) 2022-03-13
MX2017007651A (es) 2017-10-11
EA202290017A1 (ru) 2022-03-22
JP7033642B2 (ja) 2022-03-10
EP4620526A3 (fr) 2025-12-10
KR101996245B1 (ko) 2019-07-05
WO2016092042A1 (fr) 2016-06-16
EP3229794C0 (fr) 2025-11-05
PH12017501060A1 (en) 2018-03-05
EA039629B1 (ru) 2022-02-18
PH12017501060B1 (en) 2022-03-25
JP2021059574A (ja) 2021-04-15
HRP20251463T1 (hr) 2026-01-16
CY2022011I1 (el) 2022-07-22
US20240131009A1 (en) 2024-04-25
SG11201704569SA (en) 2017-07-28
AU2015359306B2 (en) 2020-07-23
MX2021005516A (es) 2022-09-27
BR112017012396B1 (pt) 2023-12-12
US20240139160A1 (en) 2024-05-02
US20210338640A1 (en) 2021-11-04
UA122063C2 (uk) 2020-09-10
US20190175563A1 (en) 2019-06-13
KR20170095302A (ko) 2017-08-22
JP2019011343A (ja) 2019-01-24
US12409167B2 (en) 2025-09-09
EP4620526A2 (fr) 2025-09-24
US11672783B2 (en) 2023-06-13
IL288907A (en) 2022-02-01
MA41481B1 (fr) 2022-03-31
CA2964616C (fr) 2020-01-28
EA201791260A1 (ru) 2017-10-31
CN106999462A (zh) 2017-08-01
JP2017537129A (ja) 2017-12-14
CY2022011I2 (el) 2022-07-22
CN106999462B (zh) 2020-10-23
BR112017012396A2 (pt) 2018-04-24
EP3229794A1 (fr) 2017-10-18
CA2964616A1 (fr) 2016-06-16
EP3229794B1 (fr) 2025-11-05
AU2015359306A1 (en) 2017-07-27
JP6846392B2 (ja) 2021-03-24
US20250375426A1 (en) 2025-12-11
KR20210122315A (ko) 2021-10-08
CL2017001479A1 (es) 2018-02-09
JP6437119B2 (ja) 2018-12-12

Similar Documents

Publication Publication Date Title
FR22C1021I2 (fr) Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif
MA41139A (fr) Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
PL3494133T3 (pl) Receptory limfocytów t anty-kras-g12d
DK3440105T3 (da) T-cellereceptorer
DK3440106T3 (da) T-cellereceptorer
DK3368060T3 (da) Glugacon-receptor-agonister
DK3362470T3 (da) Kimære antigenreceptorer indeholdende et chlorotoxindomæne
DK3194434T3 (da) Kimære antigenreceptorer
EP3302634C0 (fr) Dispositif d'administration de médicaments
DK3331886T3 (da) Dopamin-d3-receptorantagonister med en bicyclo-del
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
LT3713928T (lt) Nauji bradikinino b2 receptoriaus antagonistai
DK3484776T3 (da) Påfyldningsanordning
LT3684813T (lt) Agonistiniai cd40 antikūnai
FR3029090B1 (fr) Ensemble comportant un aerographe
DK3703912T3 (da) Ekstra støtteindretning til en emneunderstøtningsindretning
EP3529267C0 (fr) Récepteur de lymphocytes t
DK3350409T3 (da) Støtteindretning til et tætningsorgan til en borehulsprop
EP3396174A4 (fr) Dispositif de soupape
EP3551657A4 (fr) Récepteurs de chlorotoxines chimériques
EP3438359A4 (fr) Dispositif de toilettes
MA42103A (fr) Régime posologique à base de modulateur sélectif du récepteur de la progestérone (rpm)
DK3247429T3 (da) Indretning til en lægemiddeladministrationsanordning
DK3142666T3 (da) 5-HT4-receptoragonist til gastroparese
FI20150282A7 (fi) Laite kauhan täyttämiseksi